ivonescimab

News

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

News

Image of whispered gossip between two people

Summit climbs on rumour of $15bn AstraZeneca interest

Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?

News

Summit shrugs off survival miss with its VEGF bispecific

Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.

News

Dr Yu Xia, founder, chairwoman, president and chief executive of Akeso

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Mixed data from lung cancer trials on show at WCLC

Summit climbs on rumour of $15bn AstraZeneca interest

Summit shrugs off survival miss with its VEGF bispecific

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

BioNTech buys Biotheus and its Keytruda rival for $950m

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ivonescimab

Editor's Picks